2021
DOI: 10.1016/j.radonc.2020.12.027
|View full text |Cite
|
Sign up to set email alerts
|

The use of pentoxifylline, tocopherol and clodronate in the management of osteoradionecrosis of the jaws

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
31
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 24 publications
(36 citation statements)
references
References 32 publications
4
31
0
Order By: Relevance
“…This may range from simple conservative management to surgical debridement or medical management using pentoxifylline, tocopherol and clodronate. The latter treatment is showing promising results 17 but is still not considered standard treatment.…”
Section: Suspicion Of Osteoradionecrosismentioning
confidence: 99%
“…This may range from simple conservative management to surgical debridement or medical management using pentoxifylline, tocopherol and clodronate. The latter treatment is showing promising results 17 but is still not considered standard treatment.…”
Section: Suspicion Of Osteoradionecrosismentioning
confidence: 99%
“…These studies belonged to eight types – see Figure 1. For example, of these 27 included studies, two RCTs (Bairati et al, 2005; Chitra & Shyamaladevi, 2011)—see Table 1, two were systematic reviews (Kolokythas et al, 2019a; Martos‐Fernández et al, 2018)—see Table 2, six were retrospective studies (D’Souza et al, 2014; Hayashi et al, 2015; McLeod et al, 2012; Patel et al, 2016, 2021; Robard et al, 2014)—see Table 3, five were observational studies (i.e. one study was a cross‐sectional study (Dhanda et al, 2018), two were prospective studies (Delanian et al, 2005, 2011), and two were pilot studies (Bulsara et al, 2019; Futran et al, 1997))—see Table 4, seven were narrative reviews (Costa et al, 2016; Haroun & Coblens, 2019; Lyons & Brennan, 2017; Lyons & Ghazali, 2008; McCaul, 2014; Patel & McGurk, 2017; Rivero et al, 2017)—see Table 5, four articles were case reports (Bohn et al, 2016; Breik et al, 2019; Kahenasa et al, 2012; Leoncini et al, 2014)—see Table 6, and lastly one was an in ‐ vitro study (Nguyen et al, 2019)—see Table 7.…”
Section: Resultsmentioning
confidence: 99%
“…2,7 BPs are often used for the treatment of osteoporosis and osteopenia, malignant neoplasms with bone metastases, malignant hypercalcemia, and multiple myeloma [21][22][23] In addition, BP are also indicated for the treatment of Paget's disease, osteogenesis imperfecta, 8,[21][22][23][24] and osteoradionecrosis in association with other drugs. 25 Considering the number of BP users worldwide, the frequency and severity of adverse effects of BP are relatively uncommon and usually of low intensity, so the benefits provided by these drugs outweigh the possible risks. 1,6 Despite this, the risk of developing BRONJ increases considerably if preventive measures are not implemented.…”
Section: Discussionmentioning
confidence: 99%